General education about federal policies impacting pharmaceutical development, approval, and reimbursement. Policies impacting public health preparedness and prevention. Policies impacting Cardiovascular health.
General education about policies impacting pharmaceutical development, approval, reimbursement, Medicare Part D and Medicare Part B, and 340B policies.
Tax issues related to the pharmaceutical industry.
Policies impacting disease prevention.
Issues related to antitrust legislation
Issues related to patent protections.
False Claims Act Amendments.
Duration: January 1, 2008
to
May 31, 2009
General Issues: Health Issues , Medicare/Medicaid , Taxation/Internal Revenue Code , Budget/Appropriations , Labor Issues/Antitrust/Workplace , Copyright/Patent/Trademark , Law Enforcement/Crime/Criminal Justice
Spending: about $980,000 (But it's complicated. Here's why.)
It can be tricky to figure out how much an organization spent on a particular lobbying engagement. The law only requires lobbyists to report the amount they were paid for federal lobbying each quarter rounded to the nearest $10,000—and if it's less than $3,000 in a given quarter (or less than $13,000 for organizations with in-house lobbyists), they don't have to disclose it at all. Plus, some organizations include spending that doesn’t belong in the report—for instance, money spent lobbying state governments or other legal work.
Agencies lobbied since 2008: U.S. Senate, House of Representatives, White House Office
Lobbyists
Lobbyists named here were listed on a filing related to this lobbying engagement. They may not be working on it now. Occasionally, a single lobbyist whose name is spelled two different ways on filings may be represented twice here.
Lobbyist
Covered positions?
Christopher Hatcher Sch.C, Treasury and LD, Rep. Scott McInnis
Sch. C, Treasury; Associate Staff, House Rules Committee; LD, Rep. Scott McInnis
Karina Lynch Staff, Sen. Spcl. Cmtee on Aging and Gov. Affrs.
Staff, Senate Special Committee on Aging; Staff, Senate Committee on Government Affairs; Senate Committees on Aging and Gov. Affairs
Susan Hirschmann COS, Rep. Van Hilleary and Majority Whip Tom DeLay
Cheryl Jaeger Shared employee, Ofc of the Speaker & Ofc of VA 07; Sr Policy Adv, Maj Leader, Rep. Cantor; Sr Policy Adv, Republican Whip, Rep. Cantor; Sr Policy Adv, Majority Whip, Rep. Blunt; Prof Staff House Committee on E & C;
Sr LA to Rep. Cox
Christopher Wilcox Regional Staff Asst & Staff Asst, Sen. Moynihan ;LA, Leg Counsel, LD & Counsel, Rep. Arcuri; LD & Counsel, Rep. Demings
Regional Staff Asst & Staff Asst, Sen. Moynihan; LA, Leg Counsel, LD & Counsel, Rep. Arcuri; LD & Counsel, Rep. Demings
Regional Staff Asst & Staff Asst, Sen. Moynihan;LA, Leg Counsel, LD & Counsel, Rep. Arcuri; LD & Counsel, Rep. Demings
Cheryl Lynch Shared employee, Ofc of the Speaker & Ofc of VA 07; Sr Policy Adv, Maj Leader, Rep. Cantor; Sr Policy Adv, Republican Whip, Rep. Cantor; Sr Policy Adv, Majority Whip, Rep. Blunt; Prof Staff House Committee on E & C;
Sr LA to Rep. Cox
Grant Barbosa Legislative Assistant, Sen. Harris; Legislative Assistant, Rep. Sander M. Levin; Congressional Hispanic Caucus Institute Fellow, Rep. Xavier Becerra.
Dan Ziegler Executive Director, Republican Study Committee; Legislative Director for Rep Doug Lamborn
Jeanne Haggerty Legislative Correspondent Senator Chuck Grassley and Senate Aging Committee (shared staff), Legislative Aide Senate Finance Committee, Health Policy Coordinator Health Subcommittee Energy and Commerce, Professional Staff Member
Alec Aramanda Prof Staff, House Cmtee on E&C; Dir Ofc of Legislation & Dir Stakeholder Engagement, Centers for Medicare & Medicaid Services; Deputy Assistant Secretary for Health Policy, Department of Health & Human Services; Domestic Policy Advisor,
Deputy Legislative Director, Leg Asst, Sen. Cruz; Leg Asst, Sen. DeMint.
DAVID E. FRANASIAK n/a
J. Steven Hart n/a
KARINA V. LYNCH n/a
George Olsen n/a
J.Steven Hart n/a
George Olson n/a
David Franasiak n/a
Bert Carp n/a
Matthew Hoekstra n/a
Melinda Maxfield n/a
Denis Dwyer n/a
Disclosures Filed
Once a lobbying engagement begins, the lobbyist or firm is required to file updates four times a year. Those updates sometimes change which lobbyists are involved or add new issues being discussed. When lobbyists stop working for a client, the firm is also supposed to file a report disclosing the end of the relationship.
1st Quarter, 2024
In Q1, Williams and Jensen, PLLC lobbied for AMGEN, Inc. , earning $60,000. The report was filed on April 18.
Original Filing: 301553137.xml
Lobbying Issues
General education about federal policies impacting pharmaceutical development, approval, and reimbursement. Policies impacting public health preparedness and prevention. Policies impacting Cardiovascular health.
Agencies Lobbied
U.S. Senate
Lobbying Issues
General education about policies impacting pharmaceutical development, approval, reimbursement, Medicare Part D and Medicare Part B, and 340B policies.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Tax issues related to the pharmaceutical industry.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Policies impacting disease prevention.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to antitrust legislation
Agencies Lobbied
U.S. Senate
Type of Issue
Labor Issues/Antitrust/Workplace
Lobbying Issues
Issues related to patent protections.
Agencies Lobbied
U.S. Senate
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
False Claims Act Amendments.
Agencies Lobbied
U.S. Senate
Type of Issue
Law Enforcement/Crime/Criminal Justice
4th Quarter, 2023
In Q4, Williams and Jensen, PLLC lobbied for AMGEN, Inc. , earning $60,000. The report was filed on Jan. 17.
Original Filing: 301526900.xml
Lobbying Issues
General education about federal policies impacting pharmaceutical development, approval, and reimbursement. Policies impacting public health preparedness and prevention. Policies impacting Cardiovascular health.
Agencies Lobbied
U.S. Senate
Lobbying Issues
General education about policies impacting pharmaceutical development, approval, reimbursement, Medicare Part D and Medicare Part B, and 340B policies.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Tax issues related to the pharmaceutical industry.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Policies impacting disease prevention.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to antitrust legislation
Agencies Lobbied
U.S. Senate
Type of Issue
Labor Issues/Antitrust/Workplace
Lobbying Issues
Issues related to patent protections.
Agencies Lobbied
U.S. Senate
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
False Claims Act Amendments.
Agencies Lobbied
U.S. Senate
Type of Issue
Law Enforcement/Crime/Criminal Justice
3rd Quarter, 2023
In Q3, Williams and Jensen, PLLC lobbied for AMGEN, Inc. , earning $60,000. The report was filed on Oct. 19, 2023.
Original Filing: 301505980.xml
Lobbying Issues
General education about federal policies impacting pharmaceutical development, approval, and reimbursement. Policies impacting public health preparedness and prevention. Policies impacting Cardiovascular health.
Agencies Lobbied
U.S. Senate
Lobbying Issues
General education about policies impacting pharmaceutical development, approval, reimbursement, Medicare Part D and Medicare Part B, and 340B policies.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Tax issues related to the pharmaceutical industry.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Policies impacting disease prevention.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to antitrust legislation
Agencies Lobbied
U.S. Senate
Type of Issue
Labor Issues/Antitrust/Workplace
Lobbying Issues
Issues related to patent protections.
Agencies Lobbied
U.S. Senate
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
False Claims Act Amendments.
Agencies Lobbied
U.S. Senate
Type of Issue
Law Enforcement/Crime/Criminal Justice
2nd Quarter, 2023
In Q2, Williams and Jensen, PLLC lobbied for AMGEN, Inc. , earning $60,000. The report was filed on July 14, 2023.
Original Filing: 301476151.xml
Lobbying Issues
General education about federal policies impacting pharmaceutical development, approval, and reimbursement. Policies impacting public health preparedness and prevention. Policies impacting Cardiovascular health.
Agencies Lobbied
U.S. Senate
Lobbying Issues
General education about policies impacting pharmaceutical development, approval, reimbursement, Medicare Part D and Medicare Part B, and 340B policies.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Tax issues related to the pharmaceutical industry.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Policies impacting disease prevention.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to antitrust legislation
Agencies Lobbied
U.S. Senate
Type of Issue
Labor Issues/Antitrust/Workplace
Lobbying Issues
Issues related to patent protections.
Agencies Lobbied
U.S. Senate
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
False Claims Act Amendments.
Agencies Lobbied
U.S. Senate
Type of Issue
Law Enforcement/Crime/Criminal Justice
1st Quarter, 2023
In Q1, Williams and Jensen, PLLC lobbied for AMGEN, Inc. , earning $60,000. The report was filed on April 19, 2023.
Original Filing: 301457281.xml
Lobbying Issues
General education about federal policies impacting pharmaceutical development, approval, and reimbursement. Policies impacting public health preparedness and prevention. Provisions included in the Consolidated Appropriations Act, FY 23 (P.L. 117-328) related to the regulation of pharmaceuticals including policies impacting Cardiovascular health.
Agencies Lobbied
U.S. Senate
Lobbying Issues
General education about policies impacting pharmaceutical development, approval, reimbursement, Medicare Part D and Medicare Part B, and 340B policies. Provisions included in the Consolidated Appropriations Act, FY 23 (P.L. 117-328) related to the regulation of pharmaceuticals.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to the pharmaceutical industry including pricing, intellectual property and tax including provisions included in the Consolidated Appropriations Act, FY 23 (PL. 117-328).
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Policies impacting disease prevention including provisions included in the Consolidated Appropriations Act, FY 23 (P.L. 117-328) related to pharmaceuticals.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to antitrust legislation
Agencies Lobbied
U.S. Senate
Type of Issue
Labor Issues/Antitrust/Workplace
Lobbying Issues
Issues related to patent protections.
Agencies Lobbied
U.S. Senate
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
False Claims Act Amendments.
Agencies Lobbied
U.S. Senate
Type of Issue
Law Enforcement/Crime/Criminal Justice
4th Quarter, 2022
In Q4, Williams and Jensen, PLLC lobbied for AMGEN, Inc. , earning $50,000. The report was filed on Jan. 19, 2023.
Original Filing: 301433781.xml
Lobbying Issues
General education about federal policies impacting pharmaceutical development, approval, and reimbursement. Policies impacting public health preparedness and prevention. Provisions included in the Consolidated Appropriations Act, FY 23 (P.L. 117-328) related to the regulation of pharmaceuticals including policies impacting Cardiovascular health.
Agencies Lobbied
U.S. Senate
Lobbying Issues
General education about policies impacting pharmaceutical development, approval, reimbursement, Medicare Part D and Medicare Part B, and 340B policies. Provisions included in the Consolidated Appropriations Act, FY 23 (P.L. 117-328) related to the regulation of pharmaceuticals.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to the pharmaceutical industry including pricing, intellectual property and tax including provisions included in the Consolidated Appropriations Act, FY 23 (PL. 117-328).
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Policies impacting disease prevention including provisions included in the Consolidated Appropriations Act, FY 23 (P.L. 117-328) related to pharmaceuticals.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to antitrust legislation.
Agencies Lobbied
U.S. Senate
Type of Issue
Labor Issues/Antitrust/Workplace
Lobbying Issues
Issues related to patent protections.
Agencies Lobbied
U.S. Senate
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
False Claims Act Amendments S. 2428.
Agencies Lobbied
U.S. Senate
Type of Issue
Law Enforcement/Crime/Criminal Justice
3rd Quarter, 2022
In Q3, Williams and Jensen, PLLC lobbied for AMGEN, Inc. , earning $50,000. The report was filed on Oct. 19, 2022.
Original Filing: 301410295.xml
Lobbying Issues
General education about federal policies impacting pharmaceutical development, approval, and reimbursement (including Medicare, Medicaid, Affordable Care Act issues). Policies impacting public health preparedness and prevention. Policies impacting U.S. address to the Covid-19 pandemic, H.R.5376, "Inflation Reduction Act of 2022" (PL 117-169). H.R. 3. H.R. 19. Policies impacting cardiovascular health.
Agencies Lobbied
U.S. Senate
Lobbying Issues
General education about policies impacting pharmaceutical development, approval, reimbursement, Medicare Part D and Medicare Part B, and 340B policies. Policies impacting U.S. address to the Covid-19 pandemic, including the American Rescue Plan Act of 2021, P.L. 117-2, H.R. 1319. Policies related to end stage renal disease treatment. H.R. 3517 and S. 1943, Increasing Access to Osteoporosis Testing for Medicare Beneficiaries Act. H.R.5376, "Inflation Reduction Act of 2022" (PL 117-169).
Agencies Lobbied
U.S. Senate
Lobbying Issues
Medicare coverage policies and issues impacting the pharmaceutical industry including pricing intellectual property, coverage, tax. H.R.5376, "Inflation Reduction Act of 2022" (PL 117-169).
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Policies impacting U.S. address to the Covid-19 pandemic, H.R.5376, "Inflation Reduction Act of 2022" (PL 117-169) issues related to Part B and 340B Programs. H.R. 3684.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to antitrust legislation, The Competition and Law Enforcement Reform Act; Issues related to Intellectual Property protection. S. 225.
Agencies Lobbied
U.S. Senate
Type of Issue
Labor Issues/Antitrust/Workplace
Lobbying Issues
Issues related to patent protections.
Agencies Lobbied
U.S. Senate
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
False Claims Act amendments S. 2428.
Agencies Lobbied
U.S. Senate
Type of Issue
Law Enforcement/Crime/Criminal Justice
2nd Quarter, 2022
In Q2, Williams and Jensen, PLLC lobbied for AMGEN, Inc. , earning $50,000. The report was filed on July 20, 2022.
Original Filing: 301389944.xml
Lobbying Issues
General education about federal policies impacting pharmaceutical development, approval, and reimbursement (including Medicare, Medicaid, Affordable Care Act issues). Policies impacting public health preparedness and prevention. Policies impacting U.S. address to the Covid-19 pandemic, including the American Rescue Plan Act of 2021, P.L. 117-2, H.R. 1319. Build Back Better Act budget, a bill to provide budget reconciliation. H.R. 3. H.R. 19. Policies impacting cardiovascular health.
Agencies Lobbied
U.S. Senate
Lobbying Issues
General education about policies impacting pharmaceutical development, approval, reimbursement, Medicare Part D and Medicare Part B, and 340B policies. Policies impacting U.S. address to the Covid-19 pandemic, including the American Rescue Plan Act of 2021, P.L. 117-2, H.R. 1319. Policies related to end stage renal disease treatment. H.R. 3517 and S. 1943, Increasing Access to Osteoporosis Testing for Medicare Beneficiaries Act. Build Back Better Act budget, a bill to provide budget reconciliation. H.R. 3. H.R. 19.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Medicare coverage policies and issues impacting the pharmaceutical industry including pricing intellectual property, coverage, tax. Tax issues related to Build Back Better Act, H.R. 5376.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Policies impacting U.S. address to the Covid-19 pandemic, including the American Rescue Plan Act of 2021, P.L. 117-2, H.R. 1319. H.R. 3684.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to antitrust legislation, The Competition and Law Enforcement Reform Act; Issues related to Intellectual Property protection. S. 225.
Agencies Lobbied
U.S. Senate
Type of Issue
Labor Issues/Antitrust/Workplace
1st Quarter, 2022
In Q1, Williams and Jensen, PLLC lobbied for AMGEN, Inc. , earning $50,000. The report was filed on April 20, 2022.
Original Filing: 301365479.xml
Lobbying Issues
General education about federal policies impacting pharmaceutical development, approval, and reimbursement (including Medicare, Medicaid, Affordable Care Act issues). Policies impacting public health preparedness and prevention. Policies impacting U.S. address to the Covid-19 pandemic, including the American Rescue Plan Act of 2021, P.L. 117-2, H.R. 1319. Build Back Better Act budget, a bill to provide budget reconciliation. H.R. 3. H.R. 19. Policies impacting cardiovascular health.
Agencies Lobbied
U.S. Senate
Lobbying Issues
General education about policies impacting pharmaceutical development, approval, reimbursement, Medicare Part D and Medicare Part B, and 340B policies. Policies impacting U.S. address to the Covid-19 pandemic, including the American Rescue Plan Act of 2021, P.L. 117-2, H.R. 1319. Policies related to end stage renal disease treatment. H.R. 3517 and S. 1943, Increasing Access to Osteoporosis Testing for Medicare Beneficiaries Act. Build Back Better Act budget, a bill to provide budget reconciliation. H.R. 3. H.R. 19.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Medicare coverage policies and issues impacting the pharmaceutical industry including pricing intellectual property, coverage, tax. Tax issues related to Build Back Better Act, H.R. 5376.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Policies impacting U.S. address to the Covid-19 pandemic, including the American Rescue Plan Act of 2021, P.L. 117-2, H.R. 1319. H.R. 3684.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to antitrust legislation, The Competition and Law Enforcement Reform Act; Issues related to Intellectual Property protection. S. 225.
Agencies Lobbied
U.S. Senate
Type of Issue
Labor Issues/Antitrust/Workplace
4th Quarter, 2021
In Q4, Williams and Jensen, PLLC lobbied for AMGEN, Inc. , earning $50,000. The report was filed on Jan. 20, 2022.
Original Filing: 301335466.xml
Lobbying Issues
General education about federal policies impacting pharmaceutical development, approval, and reimbursement (including Medicare, Medicaid, Affordable Care Act issues). Policies impacting public health preparedness and prevention. Policies impacting U.S. address to the Covid-19 pandemic, including the American Rescue Plan Act of 2021, P.L. 117-2, H.R. 1319. Build Back Better Act budget, a bill to provide budget reconciliation. H.R. 3. H.R. 19.
Agencies Lobbied
U.S. Senate
Lobbying Issues
General education about policies impacting pharmaceutical development, approval, reimbursement, Medicare Part D and Medicare Part B, and 340B policies. Policies impacting U.S. address to the Covid-19 pandemic, including the American Rescue Plan Act of 2021, P.L. 117-2, H.R. 1319. Policies related to end stage renal disease treatment. H.R. 3517 and S. 1943, Increasing Access to Osteoporosis Testing for Medicare Beneficiaries Act. Build Back Better Act budget, a bill to provide budget reconciliation. H.R. 3. H.R. 19.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Medicare coverage policies and issues impacting the pharmaceutical industry including pricing intellectual property, coverage, tax. Tax issues related to Build Back Better Act, H.R. 5376.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Policies impacting U.S. address to the Covid-19 pandemic, including the American Rescue Plan Act of 2021, P.L. 117-2, H.R. 1319. H.R. 3684.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to antitrust legislation, The Competition and Law Enforcement Reform Act; Issues related to Intellectual Property protection. S. 225.
Agencies Lobbied
U.S. Senate
Type of Issue
Labor Issues/Antitrust/Workplace
3rd Quarter, 2021
In Q3, Williams and Jensen, PLLC lobbied for AMGEN, Inc. , earning $50,000. The report was filed on Oct. 20, 2021.
Original Filing: 301308846.xml
Lobbying Issues
General education about federal policies impacting pharmaceutical development, approval, and reimbursement (including Medicare, Medicaid, Affordable Care Act issues). Policies impacting public health preparedness and prevention. Policies impacting U.S. address to the Covid-19 pandemic, including the American Rescue Plan Act of 2021, P.L. 117-2, H.R. 1319. Build Back Better Act budget, a bill to provide budget reconciliation. H.R. 3. H.R. 19.
Agencies Lobbied
U.S. Senate
Lobbying Issues
General education about policies impacting pharmaceutical development, approval, reimbursement, Medicare Part D and Medicare Part B, and 340B policies. Policies impacting U.S. address to the Covid-19 pandemic, including the American Rescue Plan Act of 2021, P.L. 117-2, H.R. 1319. Policies related to end stage renal disease treatment. H.R. 3517 and S. 1943, Increasing Access to Osteoporosis Testing for Medicare Beneficiaries Act. Build Back Better Act budget, a bill to provide budget reconciliation. H.R. 3. H.R. 19.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Medicare coverage policies and issues impacting the pharmaceutical industry including pricing intellectual property, coverage, tax.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Policies impacting U.S. address to the Covid-19 pandemic, including the American Rescue Plan Act of 2021, P.L. 117-2, H.R. 1319. H.R. 3684.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to antitrust legislation, The Competition and Law Enforcement Reform Act; Issues related to Intellectual Property protection. S. 225.
Agencies Lobbied
U.S. Senate
Type of Issue
Labor Issues/Antitrust/Workplace
2nd Quarter, 2021
In Q2, Williams and Jensen, PLLC lobbied for AMGEN, Inc. , earning $50,000. The report was filed on July 20, 2021.
Original Filing: 301284739.xml
Lobbying Issues
General education about federal policies impacting pharmaceutical development, approval, and reimbursement (including Medicare, Medicaid, Affordable Care Act issues). Policies impacting public health preparedness and prevention. Policies impacting U.S. address to the Covid-19 pandemic, including the American Rescue Plan Act of 2021, P.L. 117-2, H.R. 1319.
Agencies Lobbied
U.S. Senate
Lobbying Issues
General education about policies impacting pharmaceutical development, approval, reimbursement, Medicare Part D and Medicare Part B, and 340B policies. Policies impacting U.S. address to the Covid-19 pandemic, including the American Rescue Plan Act of 2021, P.L. 117-2, H.R. 1319. Policies related to end stage renal disease treatment. H.R. 3517 and S. 1943, Increasing Access to Osteoporosis Testing for Medicare Beneficiaries Act.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Medicare coverage policies and issues impacting the pharmaceutical industry including pricing intellectual property, coverage, tax.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Policies impacting U.S. address to the Covid-19 pandemic, including the American Rescue Plan Act of 2021, P.L. 117-2, H.R. 1319.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to antitrust legislation, The Competition and Law Enforcement Reform Act; Issues related to Intellectual Property protection. S. 225.
Agencies Lobbied
U.S. Senate
Type of Issue
Labor Issues/Antitrust/Workplace
1st Quarter, 2021
Williams and Jensen, PLLC amended a lobbying report for representation of AMGEN, Inc. in Q12021 on April 19, 2021.
Original Filing: 301258839.xml
Lobbying Issues
General education about federal policies impacting pharmaceutical development, approval, and reimbursement (including Medicare, Medicaid, Affordable Care Act issues). Policies impacting public health preparedness and prevention. Policies impacting U.S. address to the Covid-19 pandemic, including the American Rescue Plan Act of 2021, P.L. 117-2, H.R. 1319.
Agencies Lobbied
U.S. Senate
Lobbying Issues
General education about policies impacting pharmaceutical development, approval, reimbursement, Medicare Part D and Medicare Part B, and 340B policies. Policies impacting U.S. address to the Covid-19 pandemic, including the American Rescue Plan Act of 2021, P.L. 117-2, H.R. 1319. Policies related to end stage renal disease treatment.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Medicare coverage policies and issues impacting the pharmaceutical industry including pricing intellectual property, coverage, tax.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Policies impacting U.S. address to the Covid-19 pandemic, including the American Rescue Plan Act of 2021, P.L. 117-2, H.R. 1319.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to antitrust legislation, The Competition and Law Enforcement Reform Act; Issues related to Intellectual Property protection. S. 225.
Agencies Lobbied
U.S. Senate
Type of Issue
Labor Issues/Antitrust/Workplace
1st Quarter, 2021
In Q1, Williams and Jensen, PLLC lobbied for AMGEN, Inc. , earning $50,000. The report was filed on April 19, 2021.
Original Filing: 301257464.xml
Lobbying Issues
General education about federal policies impacting pharmaceutical development, approval, and reimbursement (including Medicare, Medicaid, Affordable Care Act issues). Policies impacting public health preparedness and prevention. Policies impacting U.S. address to the Covid-19 pandemic, including the American Rescue Plan Act of 2021, P.L. 117-2, H.R. 1319.
Agencies Lobbied
U.S. Senate
Lobbying Issues
General education about policies impacting pharmaceutical development, approval, reimbursement, Medicare Part D and Medicare Part B, and 340B policies. Policies impacting U.S. address to the Covid-19 pandemic, including the American Rescue Plan Act of 2021, P.L. 117-2, H.R. 1319. Policies related to end stage renal disease treatment.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Medicare coverage policies and issues impacting the pharmaceutical industry including pricing intellectual property, coverage, tax.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Policies impacting U.S. address to the Covid-19 pandemic, including the American Rescue Plan Act of 2021, P.L. 117-2, H.R. 1319.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to antitrust legislation, The Competition and Law Enforcement Reform Act; Issues related to Intellectual Property protection. S. 225.
Agencies Lobbied
U.S. Senate
Type of Issue
Labor Issues/Antitrust/Workplace
1st Quarter, 2021
Williams and Jensen, PLLC filed a lobbying registration on Feb. 9, 2021 to represent AMGEN, Inc., effective Jan. 29, 2021.
Original Filing: 301248023.xml
Issue(s) they said they’d lobby about: Medicare coverage policies and issues impacting the pharmaceutical industry including property, coverage, tax. .
2nd Quarter, 2009
Williams & Jensen, PLLC. terminated an engagement in which they represented AMGEN on July 20, 2009.
Original Filing: 300187202.xml
Lobbying Issues
Medicare Coverage and Reimbursement Issues;
Medicaid drug rebates including S. 547/H.R. 904, Drug Rebate Equalization Act of 2009; H.R. 1725, Voluntary State Discount Prescription Drug Plan Act of 2009.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
General tax issues, and corporate taxation issues.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Follow-on biologics including H.R. 1548, the Pathway to Biosimilars Act; S. 726/H.R. 1427 ,Promoting Innovation and Access to Life-Saving Medicines Act.
Agencies Lobbied
U.S. House of Representatives
1st Quarter, 2009
In Q1, Williams & Jensen, PLLC. lobbied for AMGEN , earning $50,000. The report was filed on April 20, 2009.
Original Filing: 300160165.xml
Lobbying Issues
Medicare Coverage and Reimbursement Issues;
Medicaid drug rebates including S. 547/H.R. 904, Drug Rebate Equalization Act of 2009; H.R. 1725, Voluntary State Discount Prescription Drug Plan Act of 2009.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
General tax issues, and corporate taxation issues.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Follow-on biologics including H.R. 1548, the Pathway to Biosimilars Act; S. 726/H.R. 1427 ,Promoting Innovation and Access to Life-Saving Medicines Act.
Agencies Lobbied
U.S. House of Representatives
4th Quarter, 2008
In Q4, Williams & Jensen, PLLC. lobbied for AMGEN , earning $50,000. The report was filed on Jan. 21, 2009.
Original Filing: 300131102.xml
Lobbying Issues
Medicare Coverage and Reimbursement Issues;
Implementation of the Medicaid Drug Rebate Program.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Corporate taxation issues.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
Agencies Lobbied
U.S. House of Representatives
3rd Quarter, 2008
In Q3, Williams & Jensen, PLLC. lobbied for AMGEN , earning $50,000. The report was filed on Oct. 20, 2008.
Original Filing: 300106001.xml
Lobbying Issues
Medicare Coverage and Reimbursement Issues;
Implementation of the Medicaid Drug Rebate Program - H.R. 6331, Medicare Improvements for Patients and Providers Act.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Corporate taxation issues.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
Agencies Lobbied
U.S. House of Representatives
2nd Quarter, 2008
In Q2, Williams & Jensen, PLLC. lobbied for AMGEN , earning $50,000. The report was filed on July 18, 2008.
Original Filing: 300071584.xml
Lobbying Issues
Medicare coverage and reimbursement of Erythropoiesis-Stimulation Agents.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Corporate taxation issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
1st Quarter, 2008
In Q1, Williams & Jensen, PLLC. lobbied for AMGEN , earning $50,000. The report was filed on April 21, 2008.
Original Filing: 300049577.xml
Lobbying Issues
Medicare coverage and reimbursement of Erythropoiesis-Stimulation Agents.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Corporate taxation issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
Source: Clerk of the U.S. House of Representatives and Secretary of the Senate
Searching...